A Phase 1 interventional study of SPI-1005 and Placebo in Hearing Loss and Cancer, sponsored by Sound Pharmaceuticals, Incorporated. Completed at 1 site in United States. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-06-29.
Sponsored by Sound Pharmaceuticals, Incorporated · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 321 studies in Hearing Loss with a site in United States — 82 open to participants now, 94 under way, 3 of them phase 3. Hearing Loss · United States.
Among the 321 studies in Hearing Loss with a site in United States, this one is the 172nd largest by enrollment of the 272 interventional ones that give a count, is one of 8 that started in 2006, is one of 19 in phase 1, and was the 55th registered.
796 studies on the registry are indexed under Hearing Loss; 194 are open to participants now.
Browse Hearing Loss studies →82 of the 321 studies in Hearing Loss with a site in United States are open now. Recruiting first, the newest first:
Sound Pharmaceuticals, Incorporated · Sites in United States
Ages 18+
Skylark Bio Inc. · Sites in United States
Ages 9 mo–7 yrs
University of Arizona · Sites in United States
Ages 18+
University of Florida · Sites in United States
Ages 25–55 · Healthy volunteers
University of Arizona · Sites in United States
Ages 18–89
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 124 Hearing Loss studies recruiting now, 60 (48%) set no upper age limit and 42 (34%) stop at 75 or younger; 46 take children under 18; 46 take healthy volunteers.
This study: 19 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
321 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 31 · Phase 3 5 · Phase 4 5
First in 1997; this study’s year is marked. 8 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 44 across 561 interventional studies indexed under Hearing Loss.
Median enrollment 48 across the 272 interventional studies, 79 across the 48 observational. Of the 202 that completed or were terminated, 98 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
104 of 321 have an industry lead sponsor. The 10 most frequent:
Sound Pharmaceuticals, Incorporated is the lead sponsor of 13 studies on the registry; 2 are open to participants now.
Sound Pharmaceuticals, Incorporated has 9 studies filed under Hearing Loss — fewer than ten, so there is no comparison to draw.
34 of the studies in Hearing Loss with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06859788Phase 3Sound Pharmaceuticals, IncorporatedSPI-1005 for the Treatment of Meniere's Disease (Open Label) | 2026-12 |
| NCT05176561Gallaudet UniversityAuditory-Cognitive Training to Optimize Outcomes for Older CI Users | 2026-11 |
| NCT07913776Sonova AGPerformance of a Remote Microphone Compared to Hearing Aids Alone | 2026-11-30 |
| NCT05260307Boston University Charles River CampusImproving Spatial Perception and Speech Understanding in Multitalker Mixtures | 2026-11-30 |
| NCT06340633Sound Pharmaceuticals, IncorporatedSPI-1005 in Adults Receiving Cochlear Implant | 2026-12 |
Add all 34 to your calendar (.ics) → With an account.
Among the 321 studies in Hearing Loss with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A study to determine the safety, tolerability, and pharmacokinetics of SPI-1005 capsules in healthy adults.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lowest Dose Evaluated, 200mg Ebselen Total, Delivered as a Single Dose
Drug: SPI-1005
2x Lowest Dose Evaluated, 400mg Ebselen Total, Delivered as a Single Dose
Drug: SPI-1005
4x Lowest Dose Evaluated, 800mg Ebselen Total, Delivered as a Single Dose
Drug: SPI-1005
8x Lowest Dose Evaluated, 1600mg Ebselen Total, Delivered as a Single Dose
Drug: SPI-1005
Matching Placebo Capsule, 0mg Ebselen Total, Delivered as a Single Dose
Drug: Placebo
200 mg Ebselen oral capsules (SPI-1005), single dose
Also known as: 200 mg Ebselen
0 mg Ebselen oral capsules (SPI-1000), single dose
Also known as: 0 mg Ebselen
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
The primary objective of this study was to evaluate the safety and tolerability of SPI-1005 (ebselen) in healthy subjects. Incidence and severity of Adverse Events were determined in all treatment and placebo groups.
Time frame: 1 month
Pharmacokinetics of SPI-1005 and its major metabolites in healthy subjects
Evaluate the single dose pharmacokinetic profile of SPI-1005 in healthy subjects including Tmax, Cmax, of the parent compound and major metabolites.
Time frame: 24 hours
Plan to share: Undecided
The record gives a start of May 2006, a primary completion of Aug 2006 and a completion of Aug 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ebselen
Sound Pharmaceuticals, Incorporated